Amylyx Pharmaceuticals to Remove ALS Drug Relyvrio from US Market Following Failed Clinical Trial

Amylyx Pharmaceuticals will pull its drug, Relyvrio, from the US market after a study showed it didn't benefit patients with ALS. The drug's failure is a disappointment for patients and advocates, leaving only three ALS medicines available in the US. The company will also lay off 70% of its employees and continue studying Relyvrio and another experimental drug for rare diseases. The FDA had granted full approval for Relyvrio based on preliminary data, and the drug's withdrawal resolves a potential regulatory dilemma. ALS is a deadly disease with few treatment options, and Relyvrio's high price and disappointing sales have contributed to the decision to remove it from the market.